PREVENTIVE ROLE OF VITAMIN D SUPPLEMENTATION FOR ACUTE PHASE REACTION AFTER BISPHOSPHONATE INFUSION IN PAGET'S DISEASE.
Intravenous amino-bisphosphonates (N-BPs) can induce an acute phase reaction (APR) in up to 40-70% of first infusions, causing discomfort and often requiring intervention with analgesics or antipyretics. Our aim was to explore the risk factors of APR in a large sample of patients with Paget's disease of bone (PDB) and to assess the possible preventive effects of vitamin D administration. An observational analysis was performed in 330 PDB cases at the time of N-BP infusion. Then, an interventional study was performed in 66 patients with active, untreated PDB to evaluate if vitamin D administration (oral cholecalciferol 50000 IU/weekly for 8 weeks before infusion) may prevent APR. In retrospective study APR occurred in 47.6% and 18.3% of naive or previously treated patients, respectively. Its prevalence progressively increased in relation to the severity of vitamin D deficiency, reaching 80.0% in patients with 25OHD levels below 10 ng/ml (RR=3.7; 95%CIs 2.8-4.7, p<0.0001), even in cases previously treated with N-BPs. Moreover, APR occurred more frequently in patients who experienced a previous APR (RR=2.8; 95%CIs 1.5-5.2; p<0.001) or in carriers of SQSTM1 mutation (RR=2.3; 95%CIs 1.3-4.2; p=0.005). In the interventional study, vitamin D supplementation prevented APR in most cases, equivalent to a RR of 0.31 (95%CIs 0.14-0.67; p<0.005) with respect to prevalence rates of the observational cohort. A similar trend was observed concerning the occurrence of hypocalcaemia. The achievement of adequate 25OHD levels is recommended before N-BP infusion in order to minimize the risk of APR or hypocalcaemia in PDB.